TY  - JOUR
AU  - Paschalis, Alec
AU  - Welti, Jonathan
AU  - Neeb, Antje J
AU  - Yuan, Wei
AU  - Figueiredo, Ines
AU  - Pereira, Rita
AU  - Ferreira, Ana
AU  - Riisnaes, Ruth
AU  - Rodrigues, Daniel Nava
AU  - Jimenez-Vacas, Juan M
AU  - Kim, Soojin
AU  - Uo, Takuma
AU  - Micco, Patrizio Di
AU  - Tumber, Anthony
AU  - Islam, Md Saiful
AU  - Moesser, Marc A
AU  - Abboud, Martine
AU  - Kawamura, Akane
AU  - Gurel, Bora
AU  - Christova, Rossitza
AU  - Gil, Veronica S
AU  - Buroni, Lorenzo
AU  - Crespo, Mateus
AU  - Miranda, Susana
AU  - Lambros, Maryou B
AU  - Carreira, Suzanne
AU  - Tunariu, Nina
AU  - Alimonti, Andrea
AU  - Al-Lazikani, Bissan
AU  - Schofield, Christopher J
AU  - Plymate, Stephen R
AU  - Sharp, Adam
AU  - de Bono, Johann S
PY  - 2020
DO  - 10.1158/0008-5472.CAN-20-1807
UR  - http://hdl.handle.net/10668/17533
T2  - Cancer research
AB  - Endocrine resistance (EnR) in advanced prostate cancer is fatal. EnR can be mediated by androgen receptor (AR) splice variants, with AR splice variant 7 (AR-V7) arguably the most clinically important variant. In this study, we determined proteins key...
LA  - en
PB  - American Association for Cancer Research
KW  - Alternative splicing
KW  - Antineoplastic agents
KW  - Cell line, tumor
KW  - Cohort studies
KW  - Enzyme inhibitors
KW  - Gene expression regulation, neoplastic
KW  - Humans
KW  - Jumonji domain-containing histone demethylases
KW  - Male
KW  - Molecular targeted therapy
KW  - Oxygenases
KW  - Prognosis
KW  - Prostatic neoplasms, castration-resistant
KW  - Protein isoforms
KW  - Receptors, androgen
KW  - Retrospective studies
TI  - JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
TY  - research article
VL  - 81
ER  -